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A B S T R A C T
Background
The autoimmune regulator (AIRE) gene influences thymic self-tolerance induction. In
autoimmune polyendocrinopathy syndrome type 1 (APS1; OMIM 240300), recessive AIRE
mutations lead to autoimmunity targetting endocrine and other epithelial tissues, although
chronic candidiasis usually appears first. Autoimmunity and chronic candidiasis can associatewith
thymomas as well. Patients with these tumours frequently also have high titre immunoglobulin G
autoantibodies neutralising type I interferon (IFN)–a and IFN-x, which are secreted signalling
proteins of the cytokine superfamily involved in both innate and adaptive immunity.
Methods and Findings
We tested for serum autoantibodies to type I IFNs and other immunoregulatory cytokines
using specific binding and neutralisation assays. Unexpectedly, in 60/60 Finnish and 16/16
Norwegian APS1 patients with both AIRE alleles mutated, we found high titre neutralising
immunoglobulin G autoantibodies to most IFN-a subtypes and especially IFN-x (60%
homologous to IFN-a)—mostly in the earliest samples. We found lower titres against IFN-b
(30% homologous to IFN-a) in 23% of patients; two-thirds of these (from Finland only) also had
low titres against the distantly related ‘‘type III IFN’’ (IFN-k1; alias interleukin-29). However,
autoantibodies to the unrelated type II IFN, IFN-c, and other immunoregulatory cytokines, such
as interleukin-10 and interleukin-12, were much rarer and did not neutralise.
Neutralising titres against type I IFNs averaged even higher in patients with APS1 than in
patients with thymomas. Anti–type I IFN autoantibodies preceded overt candidiasis (and
several of the autoimmune disorders) in the informative patients, and persisted for decades
thereafter. They were undetectable in unaffected heterozygous relatives of APS1 probands
(except for low titres against IFN-k1), in APS2 patients, and in isolated cases of the endocrine
diseases most typical of APS1, so they appear to be APS1-specific.
Looking for potentially autoimmunising cell types, we found numerous IFN-aþ antigen-
presenting cells—plus strong evidence of local IFN secretion—in the normal thymic medulla
(where AIRE expression is strongest), and also in normal germinal centres, where it could
perpetuate these autoantibody responses once initiated. IFN-a2 and IFN-a8 transcripts were
also more abundant in antigen-presenting cells cultured from an APS1 patient’s blood than
from age-matched healthy controls.
Conclusions
These apparently spontaneous autoantibody responses to IFNs, particularly IFN-a and IFN-x,
segregate like a recessive trait; their high ‘‘penetrance’’ is especially remarkable for such a
variable condition. Their apparent restriction to APS1 patients implies practical value in the
clinic, e.g., in diagnosing unusual or prodromal AIRE-mutant patients with only single
components of APS1, and possibly in prognosis if they prove to predict its onset. These
autoantibody responses also raise numerous questions, e.g., about the rarity of other infections
in APS1. Moreover, there must also be clues to autoimmunising mechanisms/cell types in the
hierarchy of preferences for IFN-x, IFN-a8, IFN-a2, and IFN-b and IFN-k1.
The Editors’ Summary of this article follows the references.
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Introduction
The autoimmune regulator (AIRE) gene encodes a two-plant-
homeodomain zinc-ﬁnger protein that acts as a transcriptional
regulator [1–4]. AIRE is highly expressed in thymic medullary
epithelial cells (MECs), where it is strongly implicated in the
expression of some peripheral self-antigens and the induction
of tolerance thereto [1–6]; it is also expressed in dendritic cells
(DCs) [5], which are very potent antigen-presenting cells
(APCs). Over 50 recessive mutations have been identiﬁed in
the coding region of AIRE. In homozygotes or compound
heterozygotes, they cause autoimmune polyendocrinopathy
syndrome type 1 (APS1; OMIM 240300), also known as
autoimmune polyendocrinopathy candidiasis ectodermal dys-
trophy [2–4,6–8]. However, in at least 2% of clinically typical
patients, no mutations are found [8].
Probably through defects in AIRE protein function, in self-
antigen expression by MECs, and in self-tolerance induction
in autoreactive T cells as they are generated in the thymus,
the ensuing autoimmune attack focusses particularly on
epidermal and endocrine tissues, and features both T cells
and autoantibodies [1–4,7,8]. By deﬁnition, the patients have
at least two of the ‘‘APS1 triad’’—hypoparathyroidism (HP),
Addison disease (AD), and chronic muco-cutaneous candi-
diasis (CMC). However, the clinical phenotype is highly
variable. Characteristically, patients present with CMC and/
or skin disorders, usually early in childhood; these symptoms
are followed (sometimes 1–3 decades later) by autoimmune
endocrine disorders, which may also target the gonads and/or
endocrine cells in the gut, pancreatic islets, and thyroid gland
[3,4,7,8]. The candidiasis, which is evident early in nearly all
APS1 patients, may be due to defects in AIRE signalling
pathways involved in the handling of Candida sp. infection.
Interestingly, CMC also co-occurs with autoimmunity
(albeit against different targets) in occasional patients with
thymomas [9]. We have recently found—at diagnosis—high
titre immunoglobulin G (IgG) neutralising autoantibodies to
interferon (IFN)–a (all 12 subtypes) and IFN-x, and to
interleukin (IL)–12, in many patients with thymoma, with
late-onset myasthenia gravis (MG), and especially with
thymoma and MG together [10,11]. The human type I IFNs
all use the same receptor, and fall into ﬁve classes: IFN-a, IFN-
b, IFN-e, IFN-j, and IFN-x [12]. Only the IFN-a group
contains multiple closely related ‘‘subtypes’’, to which IFN-x
and IFN-b are about 60% and 30% related, respectively [12].
IFN-a, IFN-b, and IFN-x are inducibly expressed at very high
levels in plasmacytoid DCs and monocytes following viral
infection or stimulation through Toll-like receptors [12,13],
and are key early players in innate immune responses. In
addition, both type I IFNs and IL-12 polarise towards pro-
inﬂammatory T helper 1 responses in humans [14,15], and
perhaps less so within MG thymomas [16].
The recently identiﬁed human ‘‘type III IFNs’’, IFN-k1,
IFN-k2, and IFN-k3 (alias IL-29, IL-28A, and IL-28B,
respectively), are related structurally to, and share ;15%
homology with, type I IFNs [17,18]. They act through a
distinct receptor comprising a unique IFNLR subunit and an
IL-10Rb subunit (also part of the IL-10, IL-22, and IL-26
receptors) [17–19]. IL-10 itself is 11%–13% homologous to
the type III IFNs [17]. Like the type I IFNs, the IFN-ks are
expressed by human peripheral blood mononuclear cells and
plasmacytoid DCs upon infection with viruses or stimulation
with double-stranded RNA [17,18]. The single type II IFN,
IFN-c, shows essentially no homology to type I or III IFNs [12],
and is produced by T cells and natural killer cells.
Autoimmunising processes are very hard to study in
humans: there must be valuable clues in the thymomas, in
which we ﬁnd evidence for immunisation against IFN-a and
IL-12 [20,21]. This autoimmunisation must be highly selective,
since we have rarely found autoantibodies against many other
cytokines—even including IFN-b [10]—and never against
IFN-c [11]. Indeed, all of these autoantibodies are also rare
in many other infectious, neoplastic, or autoimmune diseases,
including sporadic multiple sclerosis and, importantly for the
present study, thyroid disease and type 1 diabetes mellitus
[11].
In view of these parallels with thymoma patients, we tested
for similar anti-cytokine autoantibodies in APS1 patients
(and controls); though generally rare, the disease is less
uncommon in Finnish (1:25,000), Sardinian (1:14,400), Iranian
Jewish (1:9,000), and Norwegian (1:80,000) populations [4,8].
We therefore screened coded serum samples from a well-
studied Finnish cohort [8], and from a further smaller group
of Norwegian APS1 patients, in validated binding enzyme-
linked immunoabsorbent assays (ELISAs) and neutralising
bioassays against type I, II, and III IFNs, IL-10, and IL-12
[10,11]. We focussed on the genetics, speciﬁcity, kinetics, and
clinical correlates of the anti-IFN autoantibodies we found,
and also tried to locate potentially autoimmunising cell types
in normal thymus and reactive tonsils.
Methods
Patients
We studied the 77 Finnish APS1 patients [8] from whom
sera were available (initially taken at ages 3.3 to 57 y [mean
19.6]). We tested 64 patients who had been AIRE-genotyped
(see Table 1) and another 13 ‘‘untyped’’ but clinically typical
APS1 patients. From 51 of the AIRE-genotyped patients, we
tested 1–5 further samples dating from 0.7 to 33 y later (mean
16). The diagnosis of APS1 was based on the classical clinical
criteria (presence of at least two of CMC, HP, and AD). The
patients had from one to eight (median four) autoimmune
manifestations, with onset from 0.7 to 20 y later (mean 6.7).
Almost all had had oral or nail candidiasis or both, since the
age of 0.2 to 30 y. Their endocrine disorders are summarised
in Table 2; in addition, 22 had alopecia (since ages 3.8–30 y),
16 had keratoconjunctivitis (1.3–16), 16 had vitiligo (0.7– 45),
six had had a period of vasculitis, and two were growth-
hormone-deﬁcient.
We also studied 17 genotyped APS1 or APS1-like patients
from Norway (16 of Norwegian and one of Pakistani origin)
[22]. The majority had at least two of the APS1 triad (see
Table 2 for endocrine disorders and Table 1 for CMC),
although one male aged 35 y had only AD ([22]; see footnote
‘‘e’’ of Table 1). Two other informative brothers in this cohort
(see footnote ‘‘b’’ of Table 1) have not yet developed AD by
ages 10 and 13 y [23].
As healthy and disease controls, we tested sera from ten
AIRE-heterozygous unaffected ﬁrst-degree relatives (six from
Finland with R257X allele and four from Norway—two with
R257X, one with 1242^1243insA, and one with 967/979del13
alleles) and from patients with APS2 (n¼ 9) or sporadic AD (n
¼ 11), HP (n ¼ 2), or CMC (n ¼ 3)—all without APS1. Six
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patients with sporadic AD and eight patients with APS2 were
found negative for the two most common APS1 AIRE
mutations, R257X and 967/979del13.
The patients with MG and thymoma have been reported on
in detail previously [10,11]; we summarise their results here
purely for comparison. All samples were taken with informed
consent and local ethical committee approval; the samples
were coded and stored at 20 8C and were diluted in the
media appropriate for cytokine-speciﬁc immunoassays and
bioassays (see below).
IFNs and Other Cytokines
IFNs and other cytokines, generously donated by the stated
manufacturers, were used in autoantibody-binding ELISA
and/or antiviral interferon neutralisation assay (AVINA)
speciﬁc for the following: recombinant human IFN-a2a
(Hoffmann-La Roche, Basel, Switzerland); other IFN-a sub-
types (BPL Laboratories, Piscataway, New Jersey, United
States); IFN-b (Biogen, Boston, Massachusetts, United States);
IFN-x (Bender and Co., Vienna, Austria); IFN-c (Roussel-
Uclaf, Romainville, France); granulocyte-macrophage colony-
stimulating factor (Immunex, Seattle, Washington, United
States); IFN-k1 [IL-29], IFN-k2 [IL-28A], and IL-4 (R&D
Systems Minneapolis, Minnesota, United States); IL-10
(Schering-Plough, Kenilworth, New Jersey, United States);
IL-12 (Hoffman-La Roche); and TNF-a (Genentech, South
San Francisco, California, United States).
Binding ELISA for the Detection of Anti-IFN and Anti-
Cytokine Autoantibodies
Microtitre wells (Dynatech, Orlando, Florida, United
States) were coated with IFN or cytokine solutions at 2 lg
protein/ml (PBS [pH 7.0]), 0.1 ml per well, for 2 h at 22 8C.
Wells were blocked with 3.0% HSA in PBS for 0.5 h at 22 8C
or overnight at 4 8C, and serially diluted sera were added for 2
h at 22 8C, before washing and development with anti-human
IgG (c-chain-speciﬁc)–alkaline phosphatase conjugate (Sigma
Chemical, St. Louis, Missouri, United States; 0.1 ml/well of
1:1,000 dilution at 22 8C for 2 h), further washing, addition of
p-nitrophenyl phosphate substrate for 0.5 h at 22 8C, and then
of 3M sodium hydroxide (0.05 ml/well); absorbances were read
at 405 nm. We considered as positive any values greater than
two standard deviations above the mean of controls.
AVINA
For type I IFNs, we pretreated the human glioblastoma cell
line 2D9 (generously provided by Dr. W. Da¨ubener; [24]) with
dilute IFN preparations (ten laboratory units [LU] per
millilitre) that had been pre-incubated for 2 h with serial
dilutions of test sera [25,26]. For IFN-ks, instead of 2D9, we
used the human glioblastoma cell line LN319 (generously
provided by Dr. A.-C. Diserens [27]), which responds well to
their antiviral activity [28]. The cells were then challenged
with encephalomyocarditis virus for 24 h, stained with 0.05%
amido blue black, ﬁxed with 4% formaldehyde in acetic acid
buffer, and stain-eluted with 0.15 ml of 0.05 M sodium
hydroxide solution before absorbance was read at 620 nm.
The neutralising antibody titre [29] was the dilution of serum
that reduces 10 LU/ml of IFN to 1 LU/ml (the normal end
point of antiviral assays [25]). The cut-off for positivity was a
titre of 40, which numerous healthy controls never exceeded.
We routinely included IFN-a1 (alias IFN-a13); its low speciﬁc
activity consistently results in ;10-fold lower neutralising
antibody titres than for any other IFN-a subtype. While these
titres generally correlate well with those for IFN-a2, they have
been omitted to avoid creating a misleading impression.
Immunohistology
Parafﬁn sections of tonsils or normal child thymus were de-
waxed, heated under pressure for 2 min in Tris:EDTA buffer
(pH 9.0), and washed in PBS. They were then stained for 1 h at
20 8C with the anti-MxA monoclonal antibody M143 (1:200
[30]), and then with sheep anti-IFN-a (1:1,000 [31,32]) for 30
min before washing and incubation with donkey anti-mouse
IgG-Alexa 594 (1:600) and anti-sheep IgG-Alexa 488 (1:400;
both from Molecular Probes, Invitrogen, Carlsbad, California,
United States), before washing and mounting.
Generation of Monocyte-Derived DCs
Buffy coats were collected from an APS1 patient with an
R257X mutation in one AIRE allele and 967/979del13 in the
other, and from two healthy blood donors; the buffy coats
were washed and then cryopreserved in liquid nitrogen. Cells
were then thawed and cultured in RPMI 1640/10% fetal calf
serum growth medium for 72 h at 37 8C in a 5% carbon
dioxide incubator. Monocytes were enriched with monoclo-
nal anti-CD14-antibody-coated microbeads (Miltenyi Biotec,
Table 1. Anti–Type I IFN Antibodies, AIRE Genotypes, and
Candidiasis in APS1 Cases from Finland and Norway
Genotype Number
of Cases
Autoantibodies
against Type I IFNs
Candidiasis
IFN-a and
IFN-x
IFN-b
R257X:R257X 40a þþ  þ
R257X:R257X 11 þþ þ þ
R257X:X546C 3 þþ  þ
R257X:C311Y 2 þþ  þ
R257X:A1758T 1 þþ þ þ
R257X:967/979del13 3b þþ  þ
R257X:967/979del13 1 þþ þ þ
R257X:1163^1164insA 1 þþ  þ
R257X:1242^1243insA 1c þþ  þ
R257X:1242^1243insA 2c þþ  
R257X:K83E 1d þþ  
R257X:Not detected 1 þþ  þ
967/979del13:967/979del13 4c þþ  þ
967/979del13:967/979del13 1c,e þþ  
967/979del13:967/979del13 3c þþ þ þ
967/979del13:967/979del13 1c þþ þ 
967/979del13:1244^1245insC 1c þþ  þ
In the anti-IFN columns a plus sign signifies a neutralising titre greater than 40; for IFN-a
and IFN-x, nearly all were far higher, and thus are designated with double plus signs.
aThere were 39 patients from Finland and one from Norway.
bThere was one patient from Finland and two from Norway, who were the informative
Norwegian brothers (see ‘‘Correlating Anti–Type I IFN Antibodies with Clinical
Components of APS1’’ in Results); by age 10 y, one has HP, CMC, keratitis, and alopecia,
and, by 13, the other has only HP and CMC.
cAll these patients were from Norway; unlettered patients are all from Finland.
dThis patient developed ungual candidiasis at age 7 y, but has never shown oral
candidiasis.
eThe unusual Norwegian patient with AD alone.
Anti–type I IFN autoantibody results were also very similar in one typical APS1 patient not
yet mentioned; she was a Caucasian female currently domiciled in New Zealand, who is
genotyped as an R257X/exon 8–deleted compound heterozygote. Her neutralising
antibody titres ranged from 500,000 against IFN-a8 and IFN-a16 and 120,000 against IFN-
x to 550 against IFN-b. She was the APS1 buffy coat donor in Figure 4.
DOI: 10.1371/journal.pmed.0030289.t001
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Bergisch Gladbach, Germany), and cultured for seven further
days with IL-4 (1,000 U/ml); granulocyte-macrophage colony-
stimulating factor (800 U/ml) was added on days 0, 3, and 6 to
yield ‘‘immature DCs’’. On day 7, some of the DCs were
matured for 3 d with monocyte-conditioned medium
prepared as previously described [33].
Quantitative Real-Time PCR
RNA was isolated using TRIzol (Life Technologies, Gai-
thersburg, Maryland, United States) and reverse-transcribed
to cDNA using the First-Strand cDNA Synthesis kit (Fermen-
tas, Burlington, Ontario, Canada). Quantitative real-time PCR
(RT-PCR) was performed with the ABI Prism 7000 SDS
instrument (Applied Biosystems, Foster City, California,
United States) using qPCR SYBR Green Core Kit (Eurogentec,
Seraing, Belgium) according to the manufacturer’s instruc-
tions, except that a 2 mM magnesium chloride concentration
was used. The ampliﬁcation program included an initial
denaturation step at 95 8C for 10 min, followed by
denaturation at 95 8C for 15 s, and annealing and extension
at 60 8C for 1 min, for 50 cycles. SYBR Green ﬂuorescence was
measured after each extension step, and the speciﬁcity of
ampliﬁcation subjected to melting curve analysis. As an
internal reference for quantiﬁcation experiments, we per-
formed RT-PCR reactions with the house-keeping genes
GAPDH and HPRT. The primers were as follows: GAPDH
forward, tccaccaccctgttgctgtag; GAPDH reverse, gaccacagtc-
catgccatcact; HPRT exon 6, gactttgctttccttggtcagg; HPRT
exon 7, agtctggcttatatccaacacttcg; IFN-x forward, gaggtacttc-
cagggaatccg; IFN-x reverse, catttcaagatgagcccaggtc; IFN-a2
forward, cctgatgaaggactccatt; IFN-a2 reverse, aaaaaggt-
gagctggcatacg; IFN-a8 forward, gtgatagagtctcccctgatgtac; and
IFN-a8 reverse, cttcaatcttttttgcaagttga [34].
Results
Autoantibodies against IFN-a and IFN-x
We ﬁrst screened for anti-IFN autoantibodies in 60 typical
Finnish APS1 patients with both AIRE alleles mutated, and
then in 16 such patients from Norway (Table 2). Both binding
and neutralising autoantibodies against IFN-a2 and IFN-x
were readily detected in the last samples from all 76 patients,
regardless of their exact clinical phenotype. These autoanti-
bodies were clearly IgG, as a speciﬁc anti-human c-chain
conjugate was used to quantify them in the ELISA. In
AVINAs, titres against IFN-a2 and IFN-x were greater than
5,000 in nearly all samples. They were generally 3- to 6-fold
higher than in MG/thymoma cases (Table 2). Since the ten
unaffected heterozygous ﬁrst-degree relatives of APS1 pa-
tients were uniformly negative in both assays (Table 2), this
response evidently segregated like a recessive trait. Moreover,
it appears to be APS1-restricted (see below). In our previous
study [11], no neutralising autoantibodies to either IFN-a2 or
IFN-x were detected in sera from 70 healthy controls.
These ﬁndings raise numerous questions about this anti-IFN
response in APS1 patients that we now address; they concern
its kinetics, its speciﬁcity for different IFN-a subtypes, other
IFNs, and other cytokines, its speciﬁcity for APS1 versus its
component diseases, its correlation with the various AIRE
genotypes, and the mechanisms of autoimmunisation.
Kinetics of anti-IFN-a and anti-IFN-x autoantibodies.
Serial samples were available from 51 Finnish patients (2–6
from each). Neutralising titres against IFN-x were already
high in the ﬁrst samples from 50 of these (Figure 1A), and
tended to be higher in the younger patients (though not
signiﬁcantly). We have no explanation for their later
appearance in the remaining patient (patient A; Table 3).
Titres were even higher against IFN-a2 than IFN-x (1.6-fold
on average) in 47 of these 51 patients, extending up to 43106
in one 3.3-y-old patient (Figure 1A); in another three of these
51 patients (patients B–D), titres were initially high against
IFN-x (.10,000; Table 3; see below), even when they were low
or undetectable against IFN-a2. Notably, in all patients tested,
neutralising antibody titres remained high for all subsequent
time points up to 30 y thereafter (Figure 1A).
Preferences for IFN-a subtypes and IFN-x. When we tested
against a panel of ten IFN-a subtypes, sequential samples
from 30/30 randomly chosen Finnish patients strongly
neutralised all of the IFN-as as well as IFN-x (Figure 2A
and 2B show a typical example). They also neutralised
‘‘leukocyte IFN preparations’’ produced by virally infected
human peripheral blood mononuclear cells in bulk (unpub-
lished data); these heterogeneous mixtures of IFN-a subtypes
plus IFN-x are representative of the IFNs produced during
viral infections of leukocytes [35]. Together, these results
argue strongly that the antibodies are recognising the native
molecules.
In general, neutralisation proﬁles (and titres) were con-
sistent between the ﬁrst and last available samples from each
patient (Figure 2A and 2B). However, there was an initial
preference for IFN-x (and/or IFN-a8) in three of the 51
patients (patients B–D; Figure 1A; Table 3) that broadened
over the following ;25 y to affect other IFN-a subtypes in
patient D (Figure 2E and 2F) and particularly IFN-a8 in
patient B (Table 3; Figure 2C and 2D). We can see no obvious
clinical explanation for the markedly higher titres in these
later samples (Table 3).
Correlations with AIRE mutations and human leukocyte
antigen genotypes. All 60 genotyped APS1 Finnish patients
with mutations in both AIRE alleles had at least one R257X
allele—which is the predominant Finnish mutation [4,8]—
whereas 12 of the 16 patients from Norway had at least one
967/979del13 mutation (Table 1). All the homozygotes—and
all the compound heterozygotes—had high titres against IFN-
a2 and IFN-x (Table 1). There may be other defects in the
AIRE or parallel pathways, as occasionally clinically typical
APS1 patients have only one identiﬁed AIRE mutation or
none at all [8]. Titres were high in the one patient with only
one identiﬁed AIRE mutation (Table 1; ‘‘x’’ in Figure 1B) and
even in two of the four individuals with no detected AIRE
mutations (‘‘y’’ and ‘‘z’’ in Figure 1B); the other two were
completely negative against all IFNs tested, but neither had
the full APS1 triad by age 39 (patients E and F; see footnote of
Table 3) and one (patient F) is the only affected member of a
sibship of 14. Titres were also high in a further 13 ‘‘untyped’’
Finnish APS1 patients (included in Figure 1B).
Both anti-IFN titres and HLA-DR and -DQ types were
available for 61 Finnish APS1 patients. HLA-DR15 was
somewhat over-represented among the cases with very high
titres (.256,000), though not signiﬁcantly so after correction
for multiple comparisons.
Correlating anti–type I IFN antibodies with clinical
components of APS1. Some patients were strongly positive
for anti-IFN antibodies despite never manifesting the full
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APS1 triad of clinical features (AD, HP, and CMC; Table 2),
including one Norwegian patient who had only AD (see
footnote ‘‘e’’ of Table 1). Similarly, titres were already high
against IFN-a2 and IFN-x at ages 3 and 7 y in two highly
informative Norwegian brothers with APS1 but no AD (see
footnote ‘‘b’’ of Table 1). At that time, both were negative for
all ten of the autoantibodies most commonly associated with
APS1 [23]; only in their next samples (;5 y later) did we
detect any of these (and then only against 21-hydroxylase [in
both brothers] and against aromatic L-amino-acid decarbox-
ylase [in the elder]; E. Husebye, unpublished data). A few
other patients were ﬁrst sampled—and already had high anti-
IFN titres—before they developed the full APS1 triad. For
example, AD began 6 and 21 y later in two Finnish patients,
and HP began 2.7 and 12 y later in two others; again, the
relevant endocrine autoantibodies probably appeared after a
considerable delay (they are usually found only shortly before
the AD [36]).
Moreover, the anti-IFN-a and anti-IFN-x antibodies were
clearly not an effect of CMC; in all the informative cases, the
antibodies antedated or coincided with the diagnosis of CMC
(Figure 1B), and they also reached high titres in the ﬁve
patients who never developed CMC overtly (one was a K85E
compound heterozygote; see footnote ‘‘d’’ of Table 1).
These antibodies are apparently restricted to APS1. They
did not reach signiﬁcant levels (.1/40) in patients with APS2
(n ¼ 9), who show characteristic adult-onset AD, thyroid
disease, and/or insulin-dependent diabetes without CMC or
HP [37], nor in patients with sporadic AD (n¼ 11), HP (n¼ 2),
or CMC (n ¼ 3), all without APS1 (Table 2).
Autoantibodies against Other Interferons and Cytokines
Surprisingly, other infections are rarely problematic in
APS1 [8], but we nevertheless screened against other
cytokines.
IFN-b. As in patients with both MG and thymoma [10,11],
we detected antibodies against the more distantly related type
I IFN, IFN-b (30% homology with IFN-a), much less
frequently than against either IFN-a or IFN-x, and at much
lower titres (Tables 1 and 2; Figure 1A); we found them mostly
in patients with especially high titres against IFN-a2 and IFN-
x (n ¼ 15), and usually from the ﬁrst sample onwards. When
positive, titres against IFN-b (in the Finnish cohort) averaged
slightly higher than in MG/thymoma patients (Table 2). They
were consistently negative in the ten unaffected hetero-
zygotes, and in patients with APS2 (n¼ 9) or sporadic cases of
AD alone (n ¼ 11), CMC alone (n ¼ 3), or HP alone (n ¼ 2)
(Table 2).
IFN-ks. These recently identiﬁed ‘‘type III’’ IFNs are ;15%
homologous to the type I IFNs [17,18]. As yet, there have been
no reports of autoantibodies to them; indeed, we found none
in the Norwegian cohort. However, we saw clear neutralisa-
tion of IFN-k1 in about two-thirds of the Finnish APS1 sera
Figure 1. Anti-IFN Neutralisation Titres in APS1 Patients at Different
Sampling Times
(A) Anti-IFN neutralisation titres in the first and last available serum
samples from 51 AIRE-genotyped Finnish patients. We use arrowheads to
mark the unusual APS1 patients A–D (detailed in Table 3), and numerals
for patients whose samples neutralised both IFN-b and IFN-k1. Bars
indicate geometric mean titres. From first to last available samples
(average interval¼ 16 y), titres were substantially increased, unchanged,
or decreased in 19%, 43%, and 38% patients, respectively.
(B) Anti-IFN neutralisation titres in Finnish APS1 patients against IFN-a2,
IFN-x, and IFN-b in the first available sera in relation to the time of
diagnosis of CMC. Results are grouped for patients sampled 1 yr prior to
diagnosis of CMC (1), at diagnosis (0), or within the indicated number of
years thereafter (0–4, 4–7, 7–10, 10–19, or .19 y). This figure excludes
four otherwise typical APS1 patients who never developed overt CMC
but who also had high titres against IFN-x (see text); it includes 63 AIRE-
genotyped and 11 untyped patients. For IFN-b, only the positive patients
are shown (for clarity). Arrowheads mark unusual APS1 patients: patients
A–E (detailed in Table 3); patient x, who currently has only one
detectable AIRE mutation; patients y and z, who are two of the three
Finnish patients with no detectable AIRE mutations; and patient E, who
meets the criteria for APS1 (Table 3), but for whom no neutralising
autoantibodies or AIRE mutations have yet been found.
DOI: 10.1371/journal.pmed.0030289.g001
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with anti-IFN-b antibodies but in very few of the others
(Table 2; numerals in Figure 1A); the 11 positive patients were
all AIRE R257X homozygotes. These autoantibodies were not
always constant, either disappearing (n ¼ 1) or appearing de
novo (n ¼ 3) several years after anti-IFN-a or anti-IFN-x
autoantibodies were ﬁrst detected. These results argue
against cross-neutralisation of IFN-b and IFN-k1 by the same
antibodies. So do the independent ﬂuctuations in titres
against IFN-b and IFN-k1 in patients 3 and 7 (Figure 1A).
Neutralisation of IFN-k2 was found only in the samples
positive against IFN-k1, and generally at lower titres (A.
Meager, unpublished data).
Notably, two of the ten unaffected heterozygotes also had
neutralising antibodies against IFN-k1 (at ages 32 and 39 y;
Table 2) but not detectably against IFN-k2. However, we
detected none of these antibodies in sera from the patients
with sporadic CMC alone (n¼ 3) or HP alone (n¼ 2) (Table 2)
or from 18 healthy controls. In MG/thymoma patients, these
autoantibodies were rare and very low in titre, even in sera
positive against IFN-b (unpublished data).
Other cytokines. We tested against other cytokines only in
the 77 Finnish sera. Against IFN-c, only ‘‘late’’ sera from two
R257X homozygous patients (one from ;28 and 37 y and the
other;17 y after onset) gavemoderate to high ELISA signals—
which we have never seen in MG/thymoma cases [10,11]—but
they showed no detectable neutralising activity; both were
strongly positive at diagnosis against IFN-a2 and IFN-x.
Against IL-12, we also found moderate levels of binding
autoantibodies in early sera from only ﬁve R257X homo-
zygous patients. Only in one of patient did the anti-IL-12
antibodies precede the anti-IFN antibodies (patient A; Table
3), and only in one other did they persist (for ;6 y).
Against IL-10, granulocyte-macrophage colony-stimulating
factor, and tumour necrosis factor–a, we found no signiﬁcant
binding in ELISAs, even though IL-10 is ;12% homologous
to the IFN-ks [17,18]. In numerous sera from many infectious,
autoimmune, and neoplastic disorders, we have very rarely
found neutralising activity without signiﬁcant binding (in
ELISAs), whereas the reverse is more common [11].
Potentially Autoimmunising Cell Types
In normal thymus. The similar anti-IFN-a autoantibodies
in APS1 and thymoma-associated MG hint at a thymic origin
for these responses. To pursue that, we next focussed on the
expression and secretion of IFN-a in sections of normal
thymus. Essentially all the IFN-aþ cells appeared to be CD68þ
APCs; we saw no signiﬁcant IFN-a labelling in cytokeratinþ
cells (not shown). Next, we double-stained for the MxA
protein that is up-regulated in cells responding to type I and
III IFNs [30]. In the cortex, as expected [31], scattered
macrophages (CD68þ) were strongly IFN-aþ, but we saw
almost no MxA labelling (Figure 3A). By contrast, in the
medulla—where AIRE is expressed most strongly [4]—there
were numerous IFN-aþ cells (Figure 3A), and MxAþ cells were
even more abundant—which is strong evidence of local
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Figure 2. Typical and Unusual Neutralisation Profiles against IFN-a
Subtypes and IFN-x
Patient (Pt) X, a Finnish R257X homozygote, has a typical profile (A and
B); patients B (C and D) and D (E and F) have unusual profiles (also
detailed in Table 3).
DOI: 10.1371/journal.pmed.0030289.g002
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secretion of type I and III IFNs. Many of the medullary IFN-aþ
cells were macrophages, and some were almost certainly DCs.
In reactive lymph-node-like tissue. Another striking feature
of the anti-IFN autoantibodies in both APS1 and thymoma/
MG patients is their prolonged persistence. We uncovered a
possible explanation while staining ‘‘normal’’ tonsils (where
others have described MxA labelling in extra-follicular areas
[38]). The most strongly stained IFN-aþ cells proved to be
CD68þ macrophage-like cells in the germinal centres.
Notably, these structures consistently also showed strong to
intermediate labelling for MxA (Figure 3B); the reticular
pattern of the labelling strongly suggests expression in
follicular dendritic cells, and hence suggests that these cells
were responding to secreted IFNs. Normally, these highly
specialised APCs play a key role in antibody diversiﬁcation by
retaining and displaying native antigens that select and
stimulate germinal centre B cells as their antibodies mutate
[39]. Thus, any native IFNs being presented there would be
ideally situated to perpetuate autoantibody responses against
them once initiated (e.g., in a thymoma [20,21]).
In APCs cultured from blood. The above ﬁndings imply
that the strongest IFN-a production is by APCs, even in the
thymus. Since no APS1 thymic cells were available, we
compared IFN expression (assessed by RT-PCR) by monocytes
and immature and mature DCs cultured from blood from a
compound heterozygous APS1 patient (with high anti-IFN-a2
and anti-IFN-x titres). For IFN-a2 and IFN-a8, the expression
levels were consistently higher in the immature DCs from this
APS1 patient than from either of two healthy controls (Figure
4A). However, the APS1/control ratios were more variable for
the CD14þ monocytes (Figure 4B) and mature DCs, and also
for IFN-x in all three cell populations (Table S1).
Discussion
In two cohorts of Nordic APS1 patients, we have now
shown almost 100% prevalences of very high titre IgG
neutralising autoantibodies against most IFN-a subtypes
and against the related, but antigenically distinct, IFN-x.
However they may be provoked, these precocious, persistent,
and highly selective responses against this narrow range of
cytokines appear to be APS1-speciﬁc and to segregate like a
Mendelian recessive trait, regardless of the exact AIRE
mutations. Their 100% ‘‘penetrance’’ in the homozygotes
and compound heterozygotes is notable because APS1 shows
such great variability both clinically and serologically
[4,7,8,22,23,36]. Moreover, the autoantibodies reached high
levels so early that, in almost every informative case, they
preceded certain of the autoimmune disorders, and also some
of the corresponding endocrine autoantibodies [36]; they
even antedated overt CMC, which is usually the earliest sign
of APS1. Clearly, these anti-IFN antibody responses cannot be
a by-product of any one of these disorders. The converse
possibilities—that type I IFNs are involved in autoimmunisa-
tion or that the antibodies predispose individuals to CMC—
are considered below. For clinicians, our ﬁndings together
imply a valuable role for these antibodies in diagnosis.
Clinical Applications
In diagnosis. It now appears that APS1 is even more
variable than previously realised; one or more of the
characteristic ‘‘APS1 triad’’ (CMC, HP, and AD) may be
missing (e.g., Tables 1 and 2)—even in patients with both
AIRE alleles mutated [22,23]. Since the anti-IFN antibodies
show such high prevalences and APS1 speciﬁcity, and appear
so early and persist so long, they should be valuable for
diagnosis of such ‘‘incomplete cases’’ (e.g., the Norwegian
brothers discussed in Results), as well as of prodromal APS1
before the appearance of its full clinical picture or of the
typical organ-speciﬁc autoantibodies. Thus, our data suggest
Figure 3. Paraffin Sections of Normal Child Thymus or Reactive Tonsil
Double-Labelled for IFN-a and MxA
(A) In the thymic cortex (C) to the left, there are scattered IFN-aþ cells
(green) with almost no nearby MxAþ cells (red), but MxAþ cells are much
more abundant in the medulla (M) to the right, especially around the
Hassall’s corpuscle at the edge. Results were similar in two other child
thymi, though one showed fewer IFN-aþ cells in the cortex. The very
dense packing precludes precise phenotyping of medullary IFN-aþ cells
in paraffin sections.
(B) Similar staining in a reactive tonsil shows a germinal centre (to the left
of the arrows) with several IFN-aþ cells and punctate labelling for MxA.
Throughout the adjacent T cell area (right), MxA is expressed strongly by
a variety of cell types, as already reported [38], whereas IFN-aþ cells are
concentrated along a small blood vessel.
DOI: 10.1371/journal.pmed.0030289.g003
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that assays against IFN-a2 and IFN-x may become the
antibody tests of choice, since they were so clearly positive
even in patients lacking the other antibodies associated with
APS1 [23]. In addition, they were clearly negative in two
further clinically doubtful cases with no AIRE mutations
detected (patients E and F see footnote of Table 3), and in
unaffected parents or siblings.
In prognosis. Antibodies against IFN-a2 and IFN-x might
also prove valuable prognostically, since titres clearly can be
extremely high even in early childhood. How long or how
frequently they precede the onset of APS1 signs is an
intriguing question that others may already be able to
address.
Infections in APS1. In theory, the anti–type I IFN antibodies
might predispose to candidiasis. So might the anti-IL-12
antibodies that we saw early and transiently in a few patients.
However, the AIRE mutations probably do so more strongly,
since this infection is rare in MG/thymoma patients (despite
their frequent additional anti-IL-12 antibodies) [11]. If these
mutations predispose via parallel pathways to CMC and anti-
IFN responses, the latter might hold clues to some even more
crucial common defect upstream. If the anti-IFN autoanti-
bodies do contribute to the candidiasis, then cautious treat-
ment with IFN-c might be considered for intractable cases
(with no anti-IFN-c antibodies); use of IFN-bmight carry some
risk of autoimmune complications [40]. Recently, Do¨fﬁnger et
al. [41] reported an extraordinary patient (aged 47) with high
titre neutralising anti-IFN-c antibodies who presented with
intractable mycobacterial infections (from which he subse-
quently died). While on IFN-c therapy (at age ;51), he
developed an APS1-like syndrome including CMC, but no
AIRE mutations were detected.
The general rarity of recurrent infections in APS1 is a
puzzle, in view of (i) the very high neutralising titres against
type I IFNs (and IL-12 in MG/thymoma patients), (ii) the role
of these IFNs (and of IL-12) in polarising towards pro-
inﬂammatory ‘‘T helper 1’’ T cell responses in humans [15],
and (iii) the asplenia in some cases (e.g., Table 3). Any
resistance of IFN-as to neutralisation in vivo might also be
relevant clinically, because treatment with anti-IFN-a anti-
bodies has been proposed for certain autoimmune disorders
such as systemic lupus erythematosus (SLE), where it is
implicated in pathogenesis [42].
Neutralisation of IFN-a evidently can occur in vivo during
therapy with IFN-a2; some patients clearly become resistant
because they make antibodies against it—usually with much
lower titres/cross-reactivity than in APS1 [43,44]. Possibly,
however, neutralising antibodies might be less effective in
vivo if IFNs secreted in tissues can bind to their receptors
before the antibodies neutralise their activity, e.g., because
IFN-producing cells are so ubiquitous and mobile or the IFNs
they release act at short range. Secondly, many viruses infect
mucosal surfaces, where locally produced IFNs may be poorly
accessible to circulating neutralising autoantibodies (we ﬁnd
no serum IgA antibodies against IFN-a in MG/thymoma
patients; A. Meager, unpublished data). Thirdly, patients with
anti-IFN antibodies may instead be protected by IFN-b or
IFN-k—which were neutralised less frequently and mostly at
much lower titres. In fact, there are occasional examples of
intractable infections in both APS1 and MG/thymoma
patients [8,10,11,21]; it may be relevant that one young child
with APS1 who had almost continuous respiratory infections
Figure 4. Expression of IFN-a2 and IFN-a8 by Immature DCs and
Monocytes Cultured from an APS1 Patient Relative to Two Healthy Blood
Donors
Expression by immature DCs (A) and monocytes (B). The APS1 donor has
typical clinical features of APS1 and high anti–type I IFN titres (see
footnote of Table 1). RT-PCR reactions were performed in parallel with
HPRT as a ‘‘house-keeping’’ gene; GADPH gave very similar results when
tested in one of the healthy donors, C1 (for IFN-a8). The relative gene
(mRNA) expression levels were calculated using the comparative Ct
(DDCt) method (according to Applied Biosystems) to yield 2DDCt, where
Ct represents the threshold cycle. Every sample was run at least three
times in three parallel reactions. Results are depicted in histogram format
as ratios of the expression levels in cells from the APS1 donor (which have
been given a nominal value of 1.0) to those in the cells from the controls,
C1 and C2. The bars represent the standard error of themean of each ratio.
DOI: 10.1371/journal.pmed.0030289.g004
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also had neutralising titres of 500–2,000 against IFN-b by age
7–9 y. Since MG/thymomas mostly arise in adulthood, we
argued [45] that such patients are well-endowed in advance
with memory T helper 1 cells that can protect against familiar
infections, even during subsequent immunosuppressive ther-
apy. That seems less likely in APS1, where onset is often so
much earlier, but where the IL-12!IFN-c axis may well be
compensating.
Comparing Findings in APS1 and MG/Thymoma Patients
Both the prevalences and the titres of the anti–type I IFN
autoantibodies are higher in APS1 patients than in MG/
thymoma patients [10,11]; they are also far higher—and much
broader in IFN-a subtype cross-reactivity—than those of
antibodies induced by therapy with IFN-a [43,44]. There are
many provocative parallels with the autoantibodies in MG/
thymoma patients [10,11]: their high titres at diagnosis
against a similar range of IFN-a subtypes, their protracted
persistence—despite immunosuppressive therapy for the MG
([11]; Figure 1A), and the constancy of their IFN-a subtype
preferences ([11]; Figure 2).
Among the differences between these two conditions, the
hitherto unrecognised autoantibodies to the IFN-ks were
barely detectable in MG/thymoma patients, even those
positive against IFN-b (A. Meager, unpublished data). In
marked contrast, anti-IL-12 antibodies were much more
common in MG/thymoma patients [10,11,45] than in patients
with APS1, where their very early transient appearance in a
few patients suggests that they might be more prevalent
before the onset of APS1.
Clues to Autoimmunising Mechanisms
There is clearly a hierarchy of cytokines recognised in
APS1, ranging from IFN-x (100%) to IFN-a8, to IFN-a2, to
IFN-b and IFN-k1/IFN-k2, to IL-12 and IFN-c (,5%). Does
that ranking reﬂect the cell types producing these cytokines,
the amounts produced, the stimuli that evoke them, or their
immunogenicity or antigenicity? Are the responses against
them initiated in the thymus or in the periphery, where AIRE
is also expressed [2–5]? Are type I IFNs involved in organ-
speciﬁc autoimmunisation in APS1? The answers to these
questions must hold valuable new clues to autoimmunising
mechanisms, which are very hard to study in humans. Other
clues include (i) the occurrence of anti-IFN-k1 autoantibodies
even in two of ten AIRE heterozygotes—which recalls the
recently reported gene dosage effects on thymic deletion in
Aireþ/mice [46]; (ii) that type I IFN therapy (e.g., for hepatitis
C) sometimes precedes a variety of autoimmune disorders
[40], including MG, SLE, sarcoidosis, and thyroid disease
[47,48]; (iii) that aberrant IFN-a production is well known in
SLE [42,49], where sporadic anti-IFN-a autoantibodies have
also been noted [50], some of which prefer IFN-a8 (D.
Isenberg and A. Meager, unpublished data); and (iv) that
autoimmunisation apparently occurs within thymomas
([20,21]; see below).
The anti–type I IFN autoantibodies might be evoked by
changes in the cells producing IFNs—which include potent
APCs. For example, DCs that produce IFN-a and IFN-b are
strongly implicated in autoimmunisation in psoriasis and
type 1 diabetes (reviewed in [51]) as well as SLE [49]. It may be
relevant that we found increased expression—particularly of
IFN-a2 and IFN-8—in blood-derived immature DCs in one
APS1 patient (Figure 4A). Because of the variability in
expression levels (especially for IFN-x and in mature DCs),
these initial experiments demand to be extended to larger
numbers of patients and controls, and above all to cells from
thymus (both APCs and MECs). The higher transcript levels in
the APS1 patient than the controls (Figure 4A) already
suggest that AIRE can have inhibitory effects. In fact, these
are now well recognised, and extend to many other genes,
such as major histocompatibility complex class II genes, and
to macrophages [52] as well as MECs [53].
Possibly, in APS1, there might be dysregulated surges in
IFN secretion in vivo, e.g., in response to childhood infections
such as Varicella; indeed, we also ﬁnd modest neutralising
titres against IFN-as, IFN-x, and IFN-k1 (but not IFN-b or
IFN-c) in some hyperimmune anti-Varicella Ig preparations
from healthy donors ([54]; A. Meager, unpublished data).
Furthermore, type I IFNs can themselves act as pro-
inﬂammatory ‘‘danger’’ signals [49] and activate APCs [55]—
and thus play a very important role in linking innate and
adaptive immune responses. Notably, too, a very early change
in newly diabetic pancreatic islets is a striking and sometimes
long-lasting up-regulation of IFN-a expression in the b cells
[32,56]. In theory, that might help to autoimmunise against
islet cell antigens; however, we have found no autoantibodies
against IFN-a or IFN-x in children with sporadic type I
diabetes (or in adults with thyroid disease) [11].
It is tempting to look in the thymus for links between APS1
and thymomas; our evidence of autoimmunisation in these
tumours [20,21] implies that expression of peripheral self-
antigens there is ‘‘dangerous’’, possibly because of pro-
inﬂammatory signals from dying cells [57] or natural killer
cells [58] that could activate DCs and invoke innate as well as
adaptive responses. Since they are clearly expressed and
secreted in the normal thymic medulla (Figure 3), type I IFNs
might, in theory, be involved in the normal induction of
tolerance there to peripheral self-antigens, or in the early
stages of autoimmunisation against them in APS1. If so, the
abnormalities in this process in AIRE-mutant patients—or
excessive cell death—might somehow lead to autoimmunisa-
tion against autoantigens such as type I IFNs thatmight be even
more abundant in the APS1 than the normal thymus; the above
hierarchy might be a valuable clue to help to identify the cell
types responsible. At a later stage, the expression—and evident
secretion—of IFN-a in germinal centres (key sites of B cell
clonal diversiﬁcation/memory generation [39]) might help to
perpetuate the autoantibody response against it, and so explain
its remarkably prolonged persistence. It might also contribute
to the induction of IFN regulatory factor–8 there, which plays
an important role in germinal centre physiology [59].
In conclusion, we demonstrate early and persistent
prevalence in APS1 patients of apparently spontaneous
neutralising autoantibodies to type I IFNs, responses that
behave like a Mendelian trait. Such high ‘‘penetrance’’ is very
unusual, even in inbred mice, and may have practical
implications for clinicians as well as researchers. Because
they are so APS1-speciﬁc and so consistent in this very
variable condition, the autoantibodies against IFN-a and
especially IFN-x should be valuable diagnostically, e.g., to
identify atypical or prodromal APS1 in patients with isolated
candidiasis, AD, or HP [23], and perhaps also for prognosis, if
they subsequently prove to predict onset time of the disease.
Finally, if the autoantibodies predispose to candidiasis, this
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condition might yield to treatment with IFN-c, which was
rarely recognised by APS1 sera.
Supporting Information
Table S1. Expression of IFN-a2, IFN-a8, and IFN-x by Monocytes and
Immature and Mature DCs Cultured from an APS1 Patient and
Healthy Blood Donors
Found at DOI: 10.1371/journal.pmed.0030289.st001 (50 KB DOC).
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Editors’ Summary
Background. The human body is under constant attack by viruses,
bacteria, fungi, and parasites, but the immune system usually prevents
these pathogens fromcausing disease. To be effective, the immune system
has to respond rapidly to foreign antigens (bits of protein specific to
pathogens) while ignoring self-antigens. If tolerance to self-antigens
breaks down, autoimmunity develops, often causing disease. There are
many common autoimmune diseases—type I diabetes and multiple
sclerosis, for example—butbecause these involvedefects inmanygenes as
well as environmental factors, the details of how autoimmunity develops
remain unclear. Autoimmune polyendocrinopathy syndrome type 1
(APS1), however, is caused by defects in a single gene. Patients with this
rare disease characteristically have defects (or mutations) in both copies of
a gene called AIRE (for autoimmune regulator). In normal people, the
protein product of this gene helps to establish tolerance to a subset of self-
antigens. People carrying AIRE mutations make an autoimmune response
against some of their own tissues, typically the endocrine (hormone-
producing) tissues that control body metabolism. A major component of
this autoimmune response are ‘‘autoantibodies’’ (antibodies are immune
molecules that normally recognize and attack foreign substances, whereas
autoantibodies are directed against the body’s own molecules).
WhyWasThisStudyDone? For adiagnosisofAPS1, apatientmusthaveat
least two of the following symptoms: recurrent, localized yeast infections
(usually the first symptom of the disease to appear in early childhood),
hypoparathyroidism (failure of the gland that controls calcium levels in the
body), and Addison disease (failure of the steroid-producing adrenal
glands, which help the body respond to stress). The researchers who did
this study had previously noticed that these yeast infections and
autoimmunity (usually against muscle) can also occur in patients with
tumors of the thymus (thymomas). The thymus is the organ that generates
immune cells called T cells. Generation of the T cell repertoire in the thymus
involves selection of those T cells that recognize only foreign substances. T
cells that can react against self-antigens are eliminated, and the AIRE gene
is thought tobe involved in this ‘‘educationprocess.’’ Like thosewithAPS1,
patients with thymomas make autoantibodies not only against target
organs (especially muscle in their case), but also against interferon alpha
(IFN-a) and interferonomega (IFN-x), two secreted immune regulators. The
researchers wanted to know if patients with APS1 also make autoanti-
bodies against interferons, because this could provide insights into how
autoimmunity develops in APS1 and other autoimmune diseases.
What Did the Researchers Do and Find? The researchers tested blood
from nearly 100 APS1 patients for antibodies to IFN-a, IFN-x, and other
immunoregulatory cytokines. They found that almost all patients made
large amounts of antibodies that blocked the function of IFN-a and IFN-x;
some also made lower amounts of antibodies against two related
interferons, but none made blocking antibodies against unrelated
interferons or other immune regulators. Formany patients, serum samples
were available at different times during their disease, which allowed the
researchers to show that the antibodies appeared early in disease
development, before the onset of yeast infections or damage to endocrine
tissues, and their production continued for decades as the patient aged.
Furthermore, only patients with APS1 made these antibodies—they were
absent in patients with Addison disease alone, for example.
WhatDoThese FindingsMean? The discovery that autoantibodies to IFN-
a and IFN-x are made persistently in patients with APS1 suggests ways in
which autoimmunity develops in these patients. These can now be
investigated further both in patients and in animal models of the disease.
The discovery also has practical implications. Measurement of these
autoantibodies might help some APS1 patients by allowing earlier
diagnosis—and prompter treatment—than in current practice. The levels
of theseautoantibodiesmightalsohelp topredict the timecourseofAPS1 in
individual patients, althoughmore studies will be needed to check this out.
Finally, if future studies show that interferon autoantibodies are responsible
for the patients’ susceptibility to yeast infections (which seems plausible),
treatment with IFN-c, an interferon to which APS1 patients do not make
autoantibodies, might provide an alternativeway to deal with this problem.
Additional Information. Please access these Web sites via the online
versionof this summaryathttp://dx.doi.org/10.1371/journal.pmed.0030289.
 MedlinePlus pages on autoimmune diseases
 Online Mendelian Inheritance in Man page on APS1
 Links to patient information on APS1 from the Stanford Health Library
 Wikipediapageonautoendocrine polyendocrinopathy (note:Wikipedia is
a free online encyclopedia that anyone can edit)
 Information on autoimmunity from the American Autoimmune Related
Diseases Association
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